Literature DB >> 31221563

Can routinely collected laboratory and health administrative data be used to assess influenza vaccine effectiveness? Assessing the validity of the Flu and Other Respiratory Viruses Research (FOREVER) Cohort.

Jeffrey C Kwong1, Sarah A Buchan2, Hannah Chung3, Michael A Campitelli3, Kevin L Schwartz2, Natasha S Crowcroft4, Michael L Jackson5, Timothy Karnauchow6, Kevin Katz7, Allison J McGeer8, J Dayre McNally9, David C Richardson10, Susan E Richardson11, Laura C Rosella2, Andrew Simor12, Marek Smieja13, George Zahariadis14, Aaron Campigotto15, Jonathan B Gubbay16.   

Abstract

BACKGROUND: Linking data on laboratory specimens collected during clinical practice with health administrative data permits highly powered vaccine effectiveness (VE) studies to be conducted at relatively low cost, but bias from using convenience samples is a concern. We evaluated the validity of using such data for estimating VE.
METHODS: We created the Flu and Other Respiratory Viruses Research (FOREVER) Cohort by linking individual-level data on respiratory virus laboratory tests, hospitalizations, emergency department visits, and physician services. For community-dwelling adults aged > 65 years, we assessed the presence and magnitude of information and selection biases, generated VE estimates under various conditions, and compared our VE estimates with those from other studies.
RESULTS: We included 65,648 unique testing episodes obtained from 54,434 individuals during the 2010-11 to 2015-16 influenza seasons. To examine information bias, we found the proportion testing positive for influenza for patients with unknown interval from illness onset to specimen collection was more similar to patients for whom illness onset date was ≤ 7 days before specimen collection than to patients for whom illness onset was > 7 days before specimen collection. To assess the presence of selection bias, we found the likelihood of influenza testing was comparable between vaccinated and unvaccinated individuals, although the adjusted odds ratios were significantly greater than 1 for some healthcare settings and during some influenza seasons. Over 6 seasons, VE estimates ranged between 36% (95%CI, 27-44%) in 2010-11 and 5% (95%CI, -2, 11%) in 2014-15. VE estimates were similar under a range of conditions, but were consistently higher when accounting for misclassification of vaccination status through a quantitative sensitivity analysis. VE estimates from the FOREVER Cohort were comparable to those from other studies.
CONCLUSIONS: Routinely collected laboratory and health administrative data contained in the FOREVER Cohort can be used to estimate influenza VE in community-dwelling older adults.
Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Bias; Data Linkage; Epidemiology; Human; Influenza; Influenza Vaccines

Year:  2019        PMID: 31221563     DOI: 10.1016/j.vaccine.2019.06.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  A Call for Caution in Use of Pertussis Vaccine Effectiveness Studies to Estimate Waning Immunity: A Canadian Immunization Research Network Study.

Authors:  Natasha S Crowcroft; Kevin L Schwartz; Rachel D Savage; Cynthia Chen; Caitlin Johnson; Ye Li; Alex Marchand-Austin; Shelly Bolotin; Shelley L Deeks; Frances B Jamieson; Steven J Drews; Margaret L Russell; Lawrence W Svenson; Kimberley Simmonds; Christiaan H Righolt; Christopher Bell; Salaheddin M Mahmud; Jeffrey C Kwong
Journal:  Clin Infect Dis       Date:  2021-07-01       Impact factor: 9.079

2.  Modeling the Impacts of Clinical Influenza Testing on Influenza Vaccine Effectiveness Estimates.

Authors:  Leora R Feldstein; Jill M Ferdinands; Wesley H Self; Adrienne G Randolph; Michael Aboodi; Adrienne H Baughman; Samuel M Brown; Matthew C Exline; D Clark Files; Kevin Gibbs; Adit A Ginde; Michelle N Gong; Carlos G Grijalva; Natasha Halasa; Akram Khan; Christopher J Lindsell; Margaret Newhams; Ithan D Peltan; Matthew E Prekker; Todd W Rice; Nathan I Shapiro; Jay Steingrub; H Keipp Talbot; M Elizabeth Halloran; Manish Patel
Journal:  J Infect Dis       Date:  2021-12-15       Impact factor: 5.226

3.  Using population-wide administrative and laboratory data to estimate type- and subtype-specific influenza vaccine effectiveness: a surveillance protocol.

Authors:  Allison Nicole Scott; Sarah A Buchan; Jeffrey C Kwong; Steven J Drews; Kimberley A Simmonds; Lawrence W Svenson
Journal:  BMJ Open       Date:  2019-09-30       Impact factor: 2.692

4.  The impact of repeated vaccination using 10-year vaccination history on protection against influenza in older adults: a test-negative design study across the 2010/11 to 2015/16 influenza seasons in Ontario, Canada.

Authors:  Jeffrey C Kwong; Hannah Chung; James Kh Jung; Sarah A Buchan; Aaron Campigotto; Michael A Campitelli; Natasha S Crowcroft; Jonathan B Gubbay; Timothy Karnauchow; Kevin Katz; Allison J McGeer; J Dayre McNally; David C Richardson; Susan E Richardson; Laura C Rosella; Kevin L Schwartz; Andrew Simor; Marek Smieja; George Zahariadis
Journal:  Euro Surveill       Date:  2020-01

5.  Validating International Classification of Disease 10th Revision algorithms for identifying influenza and respiratory syncytial virus hospitalizations.

Authors:  Mackenzie A Hamilton; Andrew Calzavara; Scott D Emerson; Mohamed Djebli; Maria E Sundaram; Adrienne K Chan; Rafal Kustra; Stefan D Baral; Sharmistha Mishra; Jeffrey C Kwong
Journal:  PLoS One       Date:  2021-01-07       Impact factor: 3.240

6.  Comparison of local influenza vaccine effectiveness using two methods.

Authors:  G K Balasubramani; Richard K Zimmerman; Heather Eng; Jason Lyons; Lloyd Clarke; Mary Patricia Nowalk
Journal:  Vaccine       Date:  2021-01-21       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.